Engineering S-scheme CuO/ZnO heterojunctions sonochemically for eradicating RhB dye from wastewater under solar radiation

In this research, S-scheme heterojunctions composed of different concentrations of CuO and ZnO nanoparticles are fabricated for eradicating rhodamine B dye under solar radiation. ZnO nanoparticles are designed through a facile sol-gel route employing Triton X-100. Spherical CuO nanoparticles of 15.2 nm and 1.5 eV band gap energy are deposited on ZnO nanoparticles in an ultrasonic bath of 300 W intensity. The physicochemical performance of the photocatalyst is explored by HRTEM, SAED, BET, XRD, DRS and PL. The in situ homogeneous growth of spherical CuO nanoparticles on ZnO active centers shifts the photocatalytic response to the deep visible region and enhances the efficiency of charge carrier separation and transportation. Among all heterojunctions, ZnCu10 containing 10 wt% CuO displays the best photocatalytic rate for expelling 93% of RhB dye within 240 min, which is twenty-fold higher than that of pristine ZnO and CuO. Reactive oxygen species are the predominant species in degrading the dye pollutant on the heterojunction surface, as shown from scrubber trapping experiments and PL spectrum of terephthalic acid. Coupling ZnO as an oxidative photocatalyst and CuO as a reductive photocatalyst generates an efficient S-scheme heterojunction with strong redox power in destructing various organic pollutants.

Induction of ovulation in women undergoing assisted reproductive techniques: recombinant human FSH (follitropin alpha) versus highly purified urinary FSH (urofollitropin HP)

This multicentre, open, randomized, study compared the efficacy and safety of recombinant follicle stimulating hormone (rFSH; follitropin alpha) with highly purified urinary human FSH (uFSH; urofollitropin HP) in women undergoing ovulation induction for assisted reproductive techniques. Following long down-regulation with buserelin, patients received two ampoules of 75 IU (150 IU) s.c. rFSH or highly purified uFSH for 6 days, after which the dose could be increased until they fulfilled the criteria for human chorionic gonadotrophin (HCG) administration. Of 168 patients recruited, 155 received at least one dose of FSH, and 137 received HCG [68: rFSH (85%); 69: uFSH (92%)]. Following oocyte retrieval and fertilization, up to three embryos were replaced/patient and luteal support was given. The mean number of oocytes retrieved/patient was 10.2 +/- 6.0 for rFSH patients compared with 10.8 +/- 6.1 in the uFSH group (not significant). There was a trend towards fewer ampoules used (22.3 +/- 6.5 versus 24.3 +/- 6.5), higher pregnancy (44.3 versus 41.4%) and live birth rates (33.8 versus 26.7%), as well as a lower miscarriage rate (0.0 versus 16.7%) in favour of rFSH. However, no significant differences in efficacy parameters were recorded. Ovarian hyperstimulation syndrome occurred in 8.6% and 7.9% of rFSH and uFSH patients respectively. In conclusion, this protocol was effective in inducing multiple follicular development and high numbers of oocytes were retrieved with both drugs.

Immunochemical purification and characterization of a 74.0-kDa Schistosoma mansoni antigen

A polypeptide antigen of 74.0 kDa molecular weight was detected in the antigenic extracts of the 3 developmental stages of Schistosoma mansoni (eggs, cercariae, and adult worms) by western blotting using BRL4 monoclonal antibody (mAb) that significantly protected mice at the levels of 51.6%, 42%, and 53.8% against challenge S. mansoni infection in 3 separate experiments. This antigen was isolated and purified from crude soluble worm antigen preparation by immunoaffinity chromatography using CNBr-activated sepharose-4B beads coupled with the BRL4 mAb. The purified antigen showed a single peak when analyzed by both high-performance liquid chromatography and high-performance capillary electrophoresis. The 74-kDa antigen was characterized as a protein in nature with 56.9% hydrophilic amino acids and 43.1% hydrophobic amino acids. This antigen was detected in 93% of urine samples from infected cases with specificity of 89% among noninfected cases using an enzyme immunoassay-fast dot-enzyme-linked immunosorbent assay based on BRL4 mAb.

Pure red-cell aplasia: a review

Pure red-cell aplasia is an anemia characterized by a near absence of nucleated red blood cells. It can be congenital or acquired. The congenital form is probably induced by intrauterine damage to early erythroid stem cells. The acquired form can be transient and self-limited or sustained and lifelong. Many, if not most, cases of transient pure red-cell aplasia are caused by the B19 parvovirus, which has a special affinity for erythroid progenitor cells. When complicating an underlying hemolytic anemia, the anemia may be acute and severe. Sustained aplasia is caused by viral invasion, immune rejection or toxic destruction of progenitor or precursor cells. It occurs most often in patients with a benign or malignant lymphoid disease. Treatment with immunosuppressive drugs--especially corticosteroids--will in most cases cause a temporary or permanent remission. The final outcome depends primarily on the underlying disorder.